Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now small index

Renal Disease clinical trials

1 of 5 indexed Renal Disease trials are currently recruiting.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Renal Disease: 5 US clinical trials tracked, 1 recruiting.

Renal Disease is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. The most active sponsor is Brigham and Women's Hospital, running 1 of these trials.

Enrollment posture brief

Registry condition renal-disease

OPEN 1 | RECR 20% | LATE 0 | EARLY 0 | RANK #3391 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Renal Disease (this)20%
Open-enrollment share among volume-matched conditions near Renal Disease

Renal Disease lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Renal Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Renal Disease is recruiting below its size-band peers.

    1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Renal Disease research.

    Brigham and Women's Hospital accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Typical Renal Disease enrolment sits around 750 participants.

    Median target enrolment is 750 among the 5 trials that report a genuine target (sentinel values excluded). 0 of those (0%) plan for fewer than 100 participants.

  4. Renal Disease research leans observational.

    2 interventional and 3 observational studies make up this index (40% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase Distribution

Phase data not available

Named interventions

Most-linked intervention names on Renal Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Active Intervention Other
1 trials
assessment Procedure
1 trials
Outlook Intervention Other
1 trials
Outlook Attention Control Other
1 trials
2nd generation SU Drug
1 trials
GLP-1RA Drug
1 trials
DPP-4 inhibitor Drug
1 trials
SGLT2 inhibitor Drug
1 trials

US sites by state

Facility locations filed on Renal Disease trials. A trial with sites in several states counts in each.

South Carolina 2 trials
North Carolina 2 trials
Alabama 2 trials
Virginia 1 trials
Texas 1 trials
Tennessee 1 trials
Mississippi 1 trials
Maryland 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Renal Disease page

5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Renal Disease condition card totals 5 registered trials; most-linked intervention Active Intervention; top US site state South Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.